Company: CERO
Filing Date: 2025-08-11
Form Type: S-3
Source: 0001213900-25-073849
Chunk: 12

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-11
Form: S-3
Chunk 12
---
 body’s full immune repertoire to achieve optimized cancer therapy. Our novel cellular immunotherapy platform is designed
to redirect patient-derived T cells to eliminate tumors by building in pathways that employ both cytotoxic and phagocytic mechanisms to
destroy cancer cells, creating what we refer to as Chimeric Engulfment Receptor T (“CER-T”) cells. Our lead molecule is CER-1236,
an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. Unlike currently approved chimeric antigen receptor (“CAR-T”)
therapies which have largely been active in hematological B cell malignancies, we believe CER-1236 will be active in both hematological
malignancies and solid tumors.

Fourth PIPE Financing

On April 21, 2025, we entered into the Fourth Securities Purchase Agreement,
pursuant to which we agreed to issue and sell up to 10,000 shares of Series D Preferred Stock for an aggregate purchase price of up to
$8 million in one or more closings. On April 22, 2025, we consummated a private placement of 6,250 shares of Series D Preferred Stock
pursuant to the Fourth Securities Purchase Agreement, by and among us and certain investors for aggregate purchase price of approximately
$5.0 million, paid through the transfer of certain Transfer Shares (as defined in the Fourth Securities Purchase Agreement) in lieu of
cash. Each additional closing of the Fourth PIPE Financing is at the option of the investors upon notice to us and subject to satisfaction
of customary closing conditions. On June 5, 2025, we sold an additional 938 shares of Series D Preferred Stock for gross cash proceeds
of $750,400 in an additional closing of the Fourth PIPE Financing.

On June 25, 2025, we
entered into an amendment to the Fourth Securities Purchase Agreement pursuant to which the Company added certain new institutional
investors to the schedule of buyers in the Fourth Securities Purchase Agreement, to issue and sell to such investors, in one or more
closings shares of the Company’s Series D Preferred Stock. Also, on June 25, 2025, we sold an additional 2,315 shares of
Series D Preferred Stock for gross cash proceeds of $1,852,000 in an additional closing of the Fourth PIPE Financing.

On July 18, 2025, we sold the remaining 497 shares of Series D Preferred
Stock issuable under